摘要
Abstract
Objective To observe the effect of eproxorubicin combined with iritecan on serum Th1 and Th2 cytokines in patients with cervical cancer. Methods From June, 2016 to December, 2018, 86 patients with cervical cancer treated at our hospital were randomly divided into two groups, 43 for each group. Extensive hysterectomy and pelvic lymph node dissection were performed in both groups. On this basis, the control group was treated with eproxorubicin, while the observation group with eproxorubicin and iritecan. The clinical efficacy, serum Th1 and Th2 cytokines, and Th1/Th2 were compared between the two groups. Results The total effective rate of the observation group was significantly higher than that of the control group (88.37％ vs. 69.77％, P<0.05). After the treatment, the IFN-γ and IL-2 were (33.05±10.55) pg/ml and (27.25±6.23) pg/ml in the observation group, which were significantly lower than those in the control group (P < 0.05). There were no statistical differences in IL-4 and IL-6 between the two groups after the treatment (both P > 0.05). After the treatment, IFN-γ/IL-4, IFN-γ/IL-6, IL-2/IL-4, and IL-2/IL-6 were in the observation group, which were lower than those in the control group (all P < 0.05). Conclusion Eproxorubicin combined with iritecan for patients with cervical cancer can effectively reduce the levels of serum Th1 and Th2 cytokines and Th1/Th2 ratio, and the clinical effect is remarkable关键词
宫颈癌/表柔比星/伊立替康/Th1、Th2细胞因子水平Key words
Cervical cancer/Epicorubicin/Iritecan/Th1 and Th2 cytokine levels
